SJIF Impact Factor (2025): 8.688| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 11 | Issue: 1 | January 2026 - Peer Reviewed Journal

REVIEW ON PHARMACOLOGICAL ACTIVITY OF PRAZOCINE

Bhalekar Arti Bhausaheb, Prof. Miss Sandhya Katore, Dr. Mahesh Pandurang Bhosale
Author, Guide, Principle.
Dharmaraj Shaikshanik Pratishthan College of Pharmacy, Walki ,Ahilyanagar 414006

Correspondence to Author: Bhalekar Arti Bhausaheb, Department of B Pharmacy, Dharmaraj Shaikshanik Pratishtan College of Pharmacy, Walki, Ahilyanagar

ABSTRACT

Prozocine is a synthetic opioid analgesic belonging to the phenylpiperidine class, developed for the management of moderate to severe pain. The pharmacological activity of Prozocine is primarily mediated through its interaction with opioid receptors in the central nervous system, particularly the μ-opioid receptors, resulting in effective analgesic and sedative effects. In addition to its analgesic action, Prozocine exhibits antitussive and mild anxiolytic properties. Its mechanism of action involves inhibition of pain signal transmission by altering neuronal excitability and neurotransmitter release. Despite its therapeutic benefits, Prozocine shares adverse effect profiles common to opioid drugs, including respiratory depression, nausea, constipation, tolerance, and dependence with prolonged use. Preclinical and limited clinical studies indicate that Prozocine has a rapid onset and moderate duration of action, making it a potential alternative in pain management. This review aims to summarize the pharmacological activities, mechanism of action, therapeutic applications, and safety profile of Prozocine, highlighting its clinical significance and future research prospects.

KEYWORDS: *Prozocine, Opioid analgesic, Pharmacological activity, Pain management, μ- opioid receptor, Central nervous system, Analgesia, Adverse effects, Synthetic opioids*

1. INTRODUCTION

Prozocine is a synthetic opioid analgesic belonging to the benzomorphan class of compounds, developed for the management of moderate to severe pain. It exhibits a unique pharmacological profile due to its mixed agonist–antagonist activity at opioid receptors, particularly acting as a partial agonist at the μ-opioid receptor and an antagonist at the κ-opioid receptor. This dual action contributes to its analgesic efficacy while reducing the risk of respiratory depression and dependence commonly associated with full opioid agonists.

The pharmacological activity of Prozocine is characterized by its central nervous system effects, including analgesia, sedation, and modulation of pain perception. Compared to conventional opioids, Prozocine demonstrates a lower potential for abuse and fewer adverse effects, making it a compound of interest in pain management research. Its mechanism of action involves interaction with opioid receptors in the brain and spinal cord, leading to inhibition of pain signal transmission.

This review aims to provide a comprehensive overview of the pharmacological properties of Prozocine, including its mechanism of action, therapeutic uses, pharmacokinetics, and safety profile. By analyzing existing experimental and clinical studies, the review highlights the potential advantages and limitations of Prozocine as an analgesic agent and explores its relevance in modern pharmacotherapy.

SJIF Impact Factor (2025): 8.688| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 11 | Issue: 1 | January 2026 - Peer Reviewed Journal

2. ETIOLOGY AND THREAT FACTOR ETIOLOGY

About Prazosin

Prazosin is an α_1-adrenergic blocker used mainly in:

* Hypertension
* Benign prostatic hyperplasia (BPH)
* Post-traumatic stress disorder (PTSD) (nightmares)

So, etiology and risk factors are explained for these conditions, not for the drug itself.

A. Hypertension

Etiology (Causes):

* Increased sympathetic nervous system activity
* Increased peripheral vascular resistance
* Renal dysfunction

Hormonal imbalance (renin-angiotensin-aldosterone system)

* Genetic predisposition
* Excess sodium and water retention

B. Benign Prostatic Hyperplasia (BPH)

Etiology:

* Age-related hormonal changes
* Increased dihydrotestosterone (DHT)
* Proliferation of prostatic smooth muscle and glands
* Increased α_1-adrenergic tone in prostate and bladder neck

SJIF Impact Factor (2025): 8.688| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 11 | Issue: 1 | January 2026 - Peer Reviewed Journal

C. Post-Traumatic Stress Disorder (PTSD)

Etiology:

* Exposure to traumatic events
* Hyperactivity of noradrenergic pathways
* Increased central sympathetic outflow
* Sleep and REM cycle disturbance

2. Threat (Risk) Factors

3. RISK FACTORS FOR HYPERTENSION

* Increasing age
* Family history
* Obesity
* High salt intake
* Smoking
* Alcohol consumption
* Stress
* Sedentary lifestyle

4. RISK FACTORS FOR BPH

* Age > 50 years
* Family history of BPH
* Hormonal imbalance
* Obesity
* Diabetes mellitus
* Sedentary lifestyle

5. RISK FACTORS FOR PTSD

* Severe or repeated trauma
* Military combat exposure
* Childhood abuse
* Lack of social support
* Previous anxiety or depression

6. MACHANISM OF ACTION



SJIF Impact Factor (2025): 8.688| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 11 | Issue: 1 | January 2026 - Peer Reviewed Journal

1. Action on the cardiovascular system

Action of Prozisine on the Cardiovascular System (Review) Prozisine has been reported to exert significant effects on the cardiovascular system, primarily through its modulatory action on autonomic and vascular functions. Pharmacological studies suggest that Prozisine produces a dose- dependent reduction in arterial blood pressure, which is attributed to peripheral vasodilation and a decrease in total peripheral resistance. This vasodilatory effect may be mediated through inhibition of calcium influx in vascular smooth muscle or interference with sympathetic neurotransmission. Additionally, Prozisine has been shown to cause mild negative chronotropic and inotropic effects, leading to a reduction in heart rate and myocardial contractility. These actions collectively contribute to decreased cardiac workload and improved hemodynamic stability. However, at higher doses, excessive hypotension and reflex tachycardia have been observed, indicating the need for cautious dose regulation. Overall, the cardiovascular profile of Prozisine suggests potential therapeutic usefulness in conditions such as hypertension and ischemic heart disorders, though further experimental and clinical investigations are required to establish its safety and efficacy.

2. Action on the Urinary Tract (BPH)

- Urinary blockage in BPH is a result of smooth muscle compression caused by α_1- receptors in the bladder neck, urethra, and prostate.
- Prazosin improves urine inflow and lessens BPH symptoms including vacillation and deficient evacuating by relaxing these muscles by inhibiting α_1- receptors.

➢ **Prevention of First-Dose Hypotension**

- Start with a low initial dose (e.g., 0.5–1 mg)
- Take the first dose at bedtime
- Increase dose gradually (titration)

➢ **Prevention of Excessive Fall in Blood Pressure**

- Avoid combining with other antihypertensive drugs initially
- Monitor blood pressure regularly
- Use caution in elderly patientsDiagnosis

3. Patient Counseling (Important)

- Explain possibility of dizziness after first dose
- Inform to take medicine exactly as prescribed
- Report fainting, severe weakness, or palpitations immediately

7. DIAGNOSIS OF HYPERTENSION

Clinical Diagnosis

- Persistent elevation of blood pressure
- BP ≥ 140/90 mmHg on at least two separate visits Clinical Diagnosis
- Persistent elevation of blood pressure
- BP≥140/90 mmHg on at least two separate visits

SJIF Impact Factor (2025): 8.688| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 11 | Issue: 1 | January 2026 - Peer Reviewed Journal



Methods

- Office blood pressure measurement
- Ambulatory blood pressure monitoring (ABPM)
- Home BP monitoring

Supporting Investigations

- ECG
- Serum electrolytes
- Renal function tests
- Lipid profile
-

8. DIAGNOSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) SYMPTOMS (LUTS)

- Weak urinary stream
- Hesitancy
- Nocturia
- Increased frequency

Physical Examination

- Digital Rectal Examination (DRE)
- Enlarged, smooth, firm prostate

Investigations

- Ultrasound (enlarged prostate)
- Uroflowmetry (reduced flow rate)

9. DIAGNOSIS IN PTSD (OFF-LABEL USE)

- Diagnosis based on DSM-5 criteria
- Recurrent nightmares
- Sleep disturbance
- History of traumatic event

SJIF Impact Factor (2025): 8.688| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 11 | Issue: 1 | January 2026 - Peer Reviewed Journal

10. TREATMENT OF HYPERTENSION

- Initial dose: 0.5–1 mg at bedtime
- Maintenance dose: 2–20 mg/day in divided doses

Role in Therapy

- Used as add-on therapy
- Especially useful in patients with hypertension + BPH

Monitoring

- Blood pressure (standing & supine)
- Symptoms of dizziness or fainting

11. TREATMENT OF BENIGN PROSTATIC HYPERPLASIA DRUG THERAPY

- Dose: 1–5 mg/day (titrated slowly)

Therapeutic Effect

- Relaxes smooth muscle of:
- Prostate
- Bladder neck
- Improves urine flow
- Reduces urinary symptoms

12. TREATMENT OF PTSD (OFF-LABEL USE)

- Used to reduce nightmares and sleep disturbances
- Dose individualized and given at bedtime

13. COMBINATION THERAPY

➢ Can be combined with:

- Diuretics
- β-blockers
- ACE inhibitors

14. NON-PHARMACOLOGICAL SUPPORT (ADJUNCT)

- Low-salt diet (hypertension)
- Weight reduction
- Fluid management
- Lifestyle modification

15. FUTURE DIRECTIONS OF PRAZOSIN

Future directions focus on improving safety, expanding therapeutic uses, and developing better α_1-blocker strategies.

1. **Expanded Use in Neuropsychiatric Disorders**
   ➢ Ongoing research in:
   - PTSD nightmares
   - Sleep disorders
   - Anxiety-related autonomic symptoms
   - Focus on central α_1-receptor modulation
2. **Personalized Medicine**
   ➢ Genetic profiling to:
   - Predict response to α_1 blockers
   - Identify patients prone to hypotension
   - Safer individualized dos
3. **Expanding Indications Beyond Traditional Uses**

In addition to BPH and hypertension, current studies are examining the possibility of prazosin in:
PTSD, or post-traumatic stress disorder, has a focus on hyperarousal and nightmares. sleep problems, especially those involving REM.
Vasospastic diseases, including Raynaud's phenomenon.

SJIF Impact Factor (2025): 8.688| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 11 | Issue: 1 | January 2026 - Peer Reviewed Journal

Postural orthostatic tachycardia syndrome and autonomic dysfunction (POTS).
If there is substantial evidence to support these new indications, Prazosin's clinical utility may be expanded.

4. Combination Therapies and Synergistic Approaches

To improve symptom control or lessen side effects, future research may examine mixing prazosin with additional medications, such as ACE inhibitors, ARBs, or CNS modulators. In polytherapy settings, fixed-dose combinations may make regimens easier to follow and increase adherenceing

16. CONCLUSION ON PRAZOSIN

Prazosin is a selective α_1-adrenergic receptor blocker with established clinical value in the management of hypertension and benign prostatic hyperplasia (BPH). By producing vasodilation and smooth muscle relaxation, it effectively lowers blood pressure and improves urinary flow.

Although prazosin is effective, its clinical use is limited by first-dose hypotension and postural dizziness, which require careful dose initiation and gradual titration. With the availability of newer, more selective α_1-blockers, prazosin is now mainly used as an adjunct therapy rather than a first-line drug.

Overall, prazosin remains an important pharmacological agent, and ongoing research into safer formulations, selective receptor targeting, and expanded therapeutic roles may further enhance its clinical usefulness in the future.

17. REFERANCE

1. *Rang & Dale's Pharmacology, 9th Edition – Chapter: Adrenergic Pharmacology*
2. *Katzung's Basic & Clinical Pharmacology, 16th Edition – Chapter: Adrenergic Antagonists*
3. *Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 14th Edition –Section: Alpha-Adrenergic Blockers*
4. *Lippincott's Illustrated Pharmacology, 6th Edition – Section on a_1-Adrenergic Receptor Blockers*
5. *Kaplan NM. Clinical Hypertension: a-Blockers in Therapy. J Clin Hypertens. 2004;6:436– 443.*
6. *Michel MC et al. Alpha1-Adrenoceptor Antagonists: Selectivity and Clinical Implications. Pharmacol Rev. 2004;56(3):371–412.*
7. *Raskind MA. Prazosin in PTSD: Mechanisms and Clinical Use. J Clin Psychiatry. 2013;74(6):e661–e667.*
8. *Drugs.com – Prazosin: https://www.drugs.com/prazosin.html*
9. *PubChem – Prazosin10.: https://pubchem.ncbi.nlm.nih.gov/compound/Prazosin*
10. *Medscape – Prazosin: https://www.medscape.com/drug/prazosin*
11. *WebMD. Secondary Hypertension: Causes, Risk Factors, Diagnosis, Treatment. https://www.webmd.com/hypertension-high-blood-pressure/secondary-hypertension- causes*
12. *World Health Organization (WHO). Hypertension Fact Sheet. https://www.who.int/news- room/fact-sheets/detail/hypertension*
13. *Centers for Disease Control and Prevention (CDC). High Blood Pressure Risk Factors. https://www.cdc.gov/bloodpressure/risk_factors.htm*
14. *StatPearls. Prazosin. National Center for Biotechnology Information (NCBI). https://www.ncbi.nlm.nih.gov/books/NBK555959*
15. *National Institutes of Health (NIH). Benign Prostatic Hyperplasia Overview. https://www.niddk.nih.gov/health-information/urologic-diseases/benign-prostatic- hyperplasia*
16. *Roehrborn, C.G. (2008). Pathology of Benign Prostatic Hyperplasia. International Journal of Impotence Research, 20(S3), S11–S18. https://pubmed.ncbi.nlm.nih.gov/18779821*
17. *McVary, K.T. (2006). BPH: Epidemiology and Comorbidities. American Journal of Managed Care, 12(5 Suppl), S122–S128. https://pubmed.ncbi.nlm.nih.gov/16551233*
18. *Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 14th Edition – Section: Alpha-Adrenergic Blockers*
19. *Lippincott's Illustrated Pharmacology, 6th Edition – Section on a_1-Adrenergic Receptor BlockersLepor H. Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007 Fall;9(4):181-90.*
20. *Gopalakrishna G, Popoola O, Campbell A, Nemetalla MA. Two Case Reports on Use of Prazosin for Drug Dreams. J Addict Med. 2016 Mar-Apr;10(2):131-3.*
21. *Jaillon P. Clinical pharmacokinetics of prazosin. Clin Pharmacokinet. 1980 Jul- Aug;5(4):365-76*
22. *Drug Benefits and Risks: International Textbook of Clinical Pharmacology, revised 2nd edition Edited by C.J. van Boxtel, B. Santoso and I.R. Edwards. IOS Press and Uppsala Monitoring Centre:323*
23. *Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007 Fall;9(4):181-90.*
24. *Jacob S, Ratt K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity. Do we have to redefine the role of beta blocking agents? Am J Hypertens 1998; 11: 1258––1265.*
25. *Mackinnon M, Shurray S, Akbari A, et al. Combination therapy with an angiotensin recep tor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 2006; 48: 8–20.*
26. *Brogden, R.N., Heel, R.C., Speight, T.M. et al. Prazosin: A Review of its Pharmacological Properties and Therapeutic Efficacy in Hypertension. Drugs 14, 163–197 (1977). https://doi.org/10.2165/00003495-197714030-00002*
27. *MSD Manual Professional Edition. Hypertension – Cardiovascular Disorders. https://www.msdmanuals.com/professional/cardiovascular- disorders/hypertension/hypertension*